Abstract: The present application concerns the treatment and prevention of diseases associated with an increased risk of sudden unexpected death in epilepsy, such as Fragile X syndrome, by administering a selective 5-HT1A receptor agonist.
Type:
Grant
Filed:
January 27, 2022
Date of Patent:
May 7, 2024
Assignees:
Neurolixis, The Regents of the University of California
Inventors:
Adrian Newman-Tancredi, Mark A. Varney, Khaleelurrahman Abdulrazak, Xin Tao
Abstract: Provided herein are compounds of the general formula (I): and pharmaceutically acceptable salts thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
Type:
Grant
Filed:
March 11, 2022
Date of Patent:
April 23, 2024
Assignee:
PFIZER INC.
Inventors:
Ketan Satish Gajiwala, Chan Woo Huh, Mehran Jalaie, Ryan Lloyd Patman, Eugene Yuanjin Rui, Jianmin Sun, Martin James Wythes
Abstract: Provided herein are bifunctional compounds having the chemical structure I: PTM-L-CLM??(I): or pharmaceutically acceptable salts thereof, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (Raf, such as c-Raf, A-Raf, and/or B-RAF) and are useful in the treatment of a variety of Raf mediated conditions or diseases, such as cancer, specifically lung cancer, skin cancer, or colorectal cancer.
Abstract: The present invention relates to bicyclic heterocycle compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are inhibitors of CD38 and are useful in the treatment of cancer.
Type:
Grant
Filed:
January 28, 2022
Date of Patent:
April 9, 2024
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Jennifer Downing, Kevin Wayne Kuntz, Laurie B. Schenkel, Melissa Marie Vasbinder
Abstract: The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid L-leucine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid and L-leucine ethyl ester is from 1:0.3 to 1:3.0 (in mol/mol) and/or hydrates and/or solvates thereof as well as to a process of obtaining the same.
Type:
Grant
Filed:
July 2, 2019
Date of Patent:
March 12, 2024
Assignee:
MERCK PATENT GMBH
Inventors:
Rudolf Moser, Viola Groehn, Ruth Boehni Stamm, Fritz Blatter, Martin Szelagiewicz
Abstract: Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
Type:
Grant
Filed:
December 18, 2018
Date of Patent:
January 23, 2024
Assignee:
Bristol-Myers Squibb Company
Inventors:
Alaric J. Dyckman, Dharmpal S. Dodd, Christopher P. Mussari, John L. Gilmore, Tasir Shamsul Haque, Trevor C. Sherwood, Brian K. Whiteley, Shoshana L. Posy, Sreekantha Ratna Kumar, Laxman Pasunoori, Srinivasan Kunchithapatham Duraisamy, Subramanya Hegde, Rushith Kumar Anumula, Pitani Veera Venkata Srinivas
Abstract: This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula I, II or any of Compounds 100-128 or any of those in Tables 2 or 3) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.
Type:
Grant
Filed:
December 28, 2020
Date of Patent:
January 2, 2024
Assignee:
Alkermes, Inc.
Inventors:
Martin R. Jefson, John A. Lowe, III, Fabian Dey, Andreas Bergmann, Andreas Schoop, Nathan Oliver Fuller
Abstract: The present invention provides triazolotriazine derivatives of formula (1) as A2A receptor antagonists. Compounds of formula (1) and pharmaceutical compositions including the compounds can be used for the treatment of disorders related to A2A receptor hyperfunctioning, such as certain types cancers. Compounds of formula (1) and methods of preparing the compounds are disclosed in the invention.
Type:
Grant
Filed:
June 26, 2018
Date of Patent:
January 2, 2024
Assignee:
ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD.
Inventors:
Sanxing Sun, Jinqi Ye, Long Zhao, Chongbo Hu, Zhengshu Chen
Abstract: The present invention provides triazolotriazine derivatives of formula (1) as A2A receptor antagonists. Compounds of formula (1) and pharmaceutical compositions including the compounds can be used for the treatment of disorders related to A2A receptor hyperfunctioning, such as certain types cancers. Compounds of formula (1) and methods of preparing the compounds are disclosed in the invention.
Type:
Grant
Filed:
June 26, 2018
Date of Patent:
December 19, 2023
Assignee:
ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD.
Inventors:
Sanxing Sun, Long Zhao, Chongbo Hu, Zhengshu Chen, Jinqi Ye
Abstract: Methods for treating one or more diseases associated with neutral sphingomyelinase 2 (nSMase2) in a subject in need of treatment thereof, the method comprising administering to the subject a therapeutically effective amount of 2,6-dimethoxy-4-(5-phenyl-4-thiophen-2-yl-1H-imidazol-2-yl)-phenol (DPTIP) or a pharmaceutically acceptable salt thereof, are disclosed.
Type:
Grant
Filed:
March 1, 2019
Date of Patent:
September 26, 2023
Inventors:
Barbara Slusher, Camilo Rojas, Ajit G. Thomas, Norman Haughey, Marc Ferrer, Xin Hu
Abstract: An embodiment relates to a crystal polymorph of 8-bromo-2-(1-methylpiperidin-4-ylamino)-4-(4-phenoxyphenylamino)pyrido [4,3-d]pyrimidin-5(6H)-one hydrochloride which can effectively suppress FLT3 and has excellent stability even in a high temperature and humid environment, and a method for preparing same.
Type:
Grant
Filed:
August 12, 2019
Date of Patent:
August 22, 2023
Assignee:
OSCOTEC INC.
Inventors:
Jung-Ho Kim, Jang-Sik Choi, Hee Kyu Lee, Song-eun Park, Dong-Sik Jung, Yung-Geun Choi, Jong-Sung Koh, Se-Won Kim, Jaekyoo Lee